Karyopharm to present SIGN Phase 2 data on gynecologic cancers
Karyopharm Therapeutics announced an oral presentation highlighting updated clinical data from the company's ongoing Phase 2 study of selinexor, its Selective Inhibitor of Nuclear Export / SINE compound that inhibits exportin 1, for the treatment of gynecological cancers. Two posters featuring predictive biomarker data supporting selinexor's activity in gynecological and colorectal cancers will also be presented. The oral presentation will describe clinical data from the study, which includes durable anti-cancer activity in gynecological malignancies with disease control rates up to 49% and good tolerability. Selinexor-associated adverse events were found to be manageable. Ovarian cancer patients receiving 50 mg/m2 of selinexor once weekly achieved similar benefit with considerably fewer adverse events compared to those receiving twice weekly dosing. Of the 59 evaluable patients with ovarian cancer, 29 met the primary endpoint for a disease control rate of 49%. Median progression free survival for the ovarian cancer arm was 3 months and median overall survival was 7 months. Of the 20 evaluable patients with endometrial cancer, 9 met the primary endpoint for a DCR of 45%. Median PFS for the endometrial cancer arm was 3 months and median OS was 8 months.